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Since the human genome sequences became available in 2001, our knowledge about the
human transposable elements which comprise ∼40% of the total nucleotides has been
expanding. Non-long terminal repeat (non-LTR) retrotransposons are actively transposing
in the present-day human genome, and have been found to cause ∼100 identified clinical
cases of varied disorders. In contrast, almost all of the human endogenous retroviruses
(HERVs) originating from ancient infectious retroviruses lost their infectivity and transpos-
ing activity at various times before the human-chimpanzee speciation (∼6 million years
ago), and no known HERV is presently infectious. Insertion of HERVs and mammalian
apparent LTR retrotransposons (MaLRs) into the chromosomal DNA influenced a number
of host genes in various modes during human evolution. Apart from the aspect of genome
evolution, HERVs and solitary LTRs being suppressed in normal biological processes can
potentially act as extra transcriptional apparatuses of cellular genes by re-activation in
individuals. There has been a reasonable prediction that aberrant LTR activation could trig-
ger malignant disorders and autoimmune responses if epigenetic changes including DNA
hypomethylation occur in somatic cells. Evidence supporting this hypothesis has begun to
emerge only recently: a MaLR family LTR activation in the pathogenesis of Hodgkin’s lym-
phoma and a HERV-E antigen expression in an anti-renal cell carcinoma immune response.
This mini review addresses the impacts of the remnant-form LTR retrotransposons on
human pathogenesis.
Keywords: human endogenous retrovirus, HERV, long terminal repeat, LTR, cancer, retrotransposon, autoimmune
HUMAN ENDOGENOUS RETROVIRUSES AND MAMMALIAN
APPARENT LTR RETROTRANSPOSONS ARE LONG TERMINAL
REPEAT-RETROTRANSPOSONS IN THE HUMAN GENOME
Endogenous retroviruses (ERVs) stem from ancient infectious
retroviruses that were reverse transcribed and integrated into
the germ cell chromosomal DNA of ancestral host animals. The
integrated viral genomes, termed proviruses, were subsequently
fixed, and have been inherited for tens of millions of years (Myr).
“Human endogenous retroviruses”(HERVs) refer to human ERVs,
most of which appear to have entered the genome after the sepa-
ration of Old and New World monkeys (∼35 Myr ago), and have
increased in copy numbers through the human/primate evolution
(1–4). The present-day human genome contains ∼400 thousand
copies of HERVs and related sequences, accounting for ∼4.6% of
the∼3 billion nucleotide sequences (5, 6). In the eras of their copy
number expansion, HERVs in the original form of 5′LTR-gag -pro-
pol-env-3′LTR amplified themselves autonomously. However, all
HERVs in the present-day humans are replication-incompetent,
having varying degrees of mutations and deletions. Despite the
absence of an obvious transposing activity, HERVs are classified
as transposons based on the evidence of transposition during the
human evolution and the existence of numerous animal ERVs
presently mobilizing in their host genomes as represented by
mouse intracisternal A particles (7, 8).
Human endogenous retroviruses are divided into 50–200 fam-
ilies primarily depending on the primer binding site (PBS)
sequences complementary to the 3′ end of a cellular tRNA (9–
11). For example, HERV-K and -W indicate utilization of tRNALys
and tRNATry as the primers for reverse transcription, respectively.
This terminology has nothing to do with their histories or func-
tions. Nevertheless, the HERV-F/H family represents the oldest
HERVs which entered into our genome before the split of simians
and prosimians∼60–70 Myr ago (12), while the HERV-K (HML-
2) family contains the youngest HERVs having the best-preserved
retroviral open reading frames (ORFs) (13, 14).
In addition to HERVs, the long terminal repeat (LTR) retro-
transposon class in humans have another big subclass of “mam-
malian apparent LTR retrotransposons” (MaLRs), which con-
sists of ∼240,000 copies accounting for 3.65% of the genomic
sequences (5) (Table 1). Despite the classification, MaLRs lack
a PBS and gag -pro-pol genes shared by animal retroelements
(Copia/Ty1, Gypsy/Ty3, etc.) and retroviruses, and are thought
to have originated before the radiation of eutherian mammals,
80–100 Myr ago (15, 16). The simple 5′LTR-ORF-3′LTR structure
without a pol gene encoding reverse transcriptase (RT) and inte-
grase suggests non-autonomous transposition. The transposon-
like human element-1 (THE1) is known as a most widespread
MaLR family in primates.
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Table 1 |Transposons in the human genome and their influences on health and diseases.
Classification Class II Class I
DNA transposons Retrotransposons
LTR retrotransposons Non-LTR retrotransposons
Members (28, 83) Super families of
MITE piggyBac,
Merlin, mutator,
etc.
Human endogenous
retroviruses (HERVs/ERVs)
Solitary LTRs LINEs (L1, L2, L3) SINEs (Alu), SVAs,
B1s pseudogenes
Mammalian apparent LTR
retrotransposons (MaLRs)
Mechanisms of
transposition or
replication (28, 83)
Autonomous,
“cut and paste”
HERV, autonomous, “copy
and paste” (13):
(1) retrotransposition,
(2) reinfection
(complementation in trans)
Autonomous, “copy
and paste” (17)
Non-autonomous,
Transposition in
trans by L1 (18, 19)
MaRL, non-autonomous (15)
Reverse transcriptase
(83)
(−) HERV(+) (−) (+) (−)
MaLR(−)
Number of copies in the
genome (×1,000) (5)
294 443 (ERV-class I, 112; class II, 8; class III, 83; Ma LR, 240) 868 (L1, 516) 1558 (SVA, 2.76;
Alu, 1,090)
Percentage (%) of the
genome (5)
2.84 8.29 (HERV, 4.64 ; MaLR, 3.65) 20.42 13.14
Structural integrity (−) (−) (+)/(−) L1 (+) (+)/(−)
Transposing activity in
present-day humans
(28)
Inactive Very limited or none (13, 35) Active (L1 only) Active with L1
Time of transposition in
human development
None reported Germline, embryo, and somatic cells (28)
Recent transposi-
tions/insertions in
evolution
∼37 Myr ago 8–17 HERV-K insertion the
past ∼6 Myr (31)
Not specified >7500 Transpositions in the past 6 Myr (23)
Impacts of the
identified elements on
human health and
homeostasis
Placenta development Alteration of cellular
gene expression by LTR
insertion (∼2 5 loci
experimentally
characterized) (45, 53)
Gene family generated by SVA through trans-
duction (AMAC, ∼7–14 Myr ago)(Syncytin-1/ERVW-1) (55, 56)
(Syncytin-2/ERVFRD-1) (57) Modulation of gene expression by Alu through
RNA editing (APOBEC3G, F11R, etc.) (19)
Transcriptional activation Hypomethylation (81) Hypomethylation (27)
Trans-activation (37) Trans-activation (SRY, RUNX3, YY1)
Disease-related
mechanisms (28, 83)
Transcriptional activation of neighboring gene Insertional mutagenesis by transposition
Viral gene expression Transduction by transposition
Recombination (hypothesized)
Related disorders None reported Hodgkin’s lymphoma (91) (activation ofCSF1R
by a THE1B LTR)
∼100 Reported cases by transposition
(columns below) (27, 28, 83)
Hypomethylation detected in malignancyRenal cell carcinoma (89, 90) (HERV-E CT-RCC-
8/9, target antigen of CD8+ cells)
Other tumors (6, 68) (expression of HERVs)
Autoimmune disorders including rheumatoid
arthritis, multiple sclerosis, Sjögren’s, and pso-
riasis (92, 100, 101) (expression of HERVs)
Facioscapulohumeral dystrophy (108) (THE1D
LTR activation by DUX4)
Hemophilia (FVIII, FIX ),
duchenne muscular
dystrophy (DMD),
neurofibromatosis type
I (NF1), tumors, etc.
Hemophilia (FVIII,
FIX ), breast cancer
(BRCA2),
neurofibromatosis
type I (NF1), etc.
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MOBILIZATION OF NON-LTR RETROTRANSPOSONS
Transposons currently mobilizing on the human chromosomes
include the long interspersed elements (LINEs), short interspersed
elements (SINEs), and “SINE-R, variable of number of tandem
repeats (VNTRs) and Alu” (SVA) elements, all of which are in the
“non-LTR retrotransposons” family. L1 elements in the LINE fam-
ily, are the only active autonomous retrotransposons, and replicate
by a simple “copy and paste” mechanism involving target-site
primed reverse transcription (17).Alu elements, the youngest sub-
types of SINEs, and SVAs are apparently mobilized in trans by L1s
(18, 19). Retrotransposition of these elements occurs in germline,
early embryonic development, and in somatic cells (20–22).
In the past 6 Myr, >7,500 transpositions occurred in the pri-
mate genome (23). One retrotransposition per 10–100 births is
estimated (19, 24). Thus, L1, Alu, and SVA elements have sub-
stantially impacted the human genome organization in evolution
(25). Furthermore, the non-LTR retrotransposons are causative
agents of human genetic disorders (26, 27); ∼100 cases of dis-
orders caused by non-LTR retrotransposon insertions have been
reported (27, 28) (Table 1).
HERVs AND MaLRs EXIST AS NON-TRANSPOSABLE
ELEMENTS
In comparison with the intra-nuclear transposition mechanisms
of non-LTR retrotransposons, both of the ERV amplification path-
ways,“retrotransposition,”and“reinfection,”are tricky. The former
comprises multiple steps including particle-like assembly in the
cytosol, reverse transcription, nuclear translocation, and chro-
mosomal insertion. The latter requires infectious virus particle
production followed by germ-line infection ultimately leading to
chromosomal integration and fixation (13, 29, 30). Defective ERVs
are also able to increase their copy numbers by “complementation
in trans,” where a matching element at a different locus serves
as the helper (13, 29). These mechanisms underlay the HERV
amplification in the past.
However, no evidence of HERV transposition has been detected
in present-day humans, either in a scientific or clinical back-
ground. Studies suggested 8–17 full-length HERV-K insertions
after the divergence of humans from chimpanzees ∼6 Myr ago
(31, 32). The insertion of HERV-K113 and -K115 were estimated
to be a minimum 0.8–1 Myr ago, and that of HERV-K106 to be
∼150,000 years ago (33, 34). Even though the possibility of the
youngest HERV-K mobilization still remains (35),HERVs as trans-
posable elements do not impose a “clear and present danger” to
humans. In addition, transposition of the older resident MaLRs is
the most improbable.
HUNDREDS OF THOUSANDS OF LTRs IN THE GENOME CAN
PROVIDE BINDING SITES FOR TRANSCRIPTION FACTORS
Solitary LTRs, or solo LTRs, were generated from existing HERVs
and MaLRs by the loss of internal sequences upon recombination
between the 5′ and 3′ LTRs within the same copies or between
separate LTRs. The human genome contains∼50 copies of ERV-9
provirus forms and 3,000–4,000 copies of ERV-9 solitary LTRs
(36). A recent study identified 944 HERV-K (HML-2) solitary
LTRs versus 91 copies of full-length and nearly full-length HERV-
K (HML-2) (14). In general, 85% of the HERV copies consist of
solitary LTRs (5). The majority of MaLRs also exist as solitary
LTRs (15).
Retrovirus LTRs (300–1300 bp) in the U3–R–U5 architecture
are essential for high-level expression of the viral sequences (37).
The U3 region contains a TATA box and transcription regulatory
sequences which govern ubiquitous or tissue-specific gene expres-
sion. For instance, the U3 regions of human immunodeficiency
viruses (HIVs) and the group of human T-cell leukemia viruses
(HTLVs) have NF-κB and CREB/ATF binding sequences, respec-
tively (38–41). Regulatory factors bind to the cognate cis-acting
sequences to induce transcription from the initiation site corre-
sponding to the 5′ terminus of the R region. In fact, the HERV-
K (HML-2) LTR has Sp1/Sp3 and microphthalmia-associated
transcription factor-M (MITF-M) binding sites in U3 (42, 43).
Therefore, the∼400,000 copies of the LTR-retroelements scat-
tered throughout the human chromosomes potentially provide
extra enhancer-promoter sequences and initiation sites for neigh-
boring cellular genes. By utilization of a nearby LTR as its alter-
native transcription machinery, one gene can give rise to new
isoforms, enhance its transcription, and alter the tissue-specificity.
In this context, HERVs and MaLRs could have significantly
influenced the human genome evolution (44).
INFLUENCE OF LTR/HERV INSERTIONS ON CELLULAR GENE
EXPRESSION IN HUMAN EVOLUTION
More than 25 experimentally characterized cellular genes show
LTR-mediated evolutionary changes, in which inserted LTRs act
as alternative promoters to provide new tissue-specificity, play
as the major promoters, or exert only minor effects (45). For
example, an ERV-L LTR plays as an alternative promoter of β1,3-
galactosyltransferase 5 gene (B3GALT5) to induce colon-specific
transcription (46). A HERV-K(HML-5) LTR serves as the major
promoter of INSL4, a primate-specific insulin-like growth factor
gene expressed in placenta (47). A HERV-E family LTR plays as
an alternative tissue-specific promoter of the endothelin B recep-
tor (EDNRB) gene, by which the gene expression increased∼15%
in placenta (48). LTR-derived promoters often increase placenta-
specific gene expression, although the overall effect of the LTR
insertion appears moderate in many cases (45). Notably, the 5′
terminus of a HERV-E insert in reversed orientation provides
a salivary-specific enhancer for the human-only amylase gene
AMY1C (49, 50).
The LTR of ERV-9 located in the β-globin locus control region
(β-LCR) serves as an additional enhancer region for the down-
stream globin genes (36, 51). The U3 region has 5–17 tandem
repeats of 37–41 bases with GAGA, CCAAT, and CCACC motifs, in
which the strong affinity of NF-Y, a ubiquitous transcriptional reg-
ulatory factor, to the CCAAT motif allows a robust enhancer com-
plex formation with other proteins (52). An ERV-9 LTR upstream
ofTP63 (p63), a member of the tumor suppressorTP53 (p53) gene
family, acts as a strong promoter to express novel p63 isoforms in
the testis of hominidae (53). Thus, some of the 5,000 copies of
ERV-9 LTRs, 15–38 Myr after their integration (54), are involved
in adjacent host gene control.
A HERV-W-derived Env glycoprotein encoded by ERVW-
1 (7q21.2) (also termed syncytin-1 or ERVWE1) causes
cytotrophoblast fusion, suggesting an essential function in
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syncytiotrophoblast formation in placenta tissue development
(55). In addition, a HERV-FRD Env protein encoded by ERVFRD-
1, or syncytin-2 (6p24), was found to have an immunosuppres-
sive activity (56), while a role in placenta morphogenesis was
also suggested (57). In conjunction with the upstream regulatory
sequences, the HERV-W LTR drives the strongERVW-1 expression
in placenta (58).
THE HYPOTHESIS OF HERV-MEDIATED ONCOGENESIS
Animal exogenous retroviruses carrying oncogenes can trigger
transformation of the host cells by expression of the viral onco-
genes (59). The virus env gene can act like an oncogene (60, 61).
Retroviruses without an oncogene are also oncogenic. If retrovi-
ral integration occurs in the vicinity of a proto-oncogene which
typically encodes a growth factor receptor, signaling molecule, or
transcriptional activator, the LTR can activate it. “Transduction”
of oncogenes and “insertional mutagenesis” by the LTRs represent
major retroviral tumorigenesis mechanisms (59, 62). Based on
the knowledge of retroviral functions, contribution of HERVs and
solitary LTRs to human tumorigenesis has long been hypothesized.
The Np9 and Rec genes overlapping the env gene of HERV-
K are particularly intriguing as candidate oncogenes. HERV-K
was found as an endogenous retrovirus expressed in teratocar-
cinoma cell lines in an earlier study (63). Nuclear protein Np9
interacts with E3 ubiquitin ligase Ligand of Numb Protein-X
(LNX), and thereby possibly influences the Notch pathway (64).
Rec transgenic mice manifest neoplastic changes in the testes which
correspond to the precursor phenotype of seminoma in humans
(65). The Rec protein enhances androgen receptor-mediated tran-
scription (66). High-level expression of Rec and Np9 also occurs
in melanoma (67).
Activation of specific or selective HERVs occurs in various
tumors and cell lines (68). HERV-K has been most extensively
analyzed in cancers from different tissue origins. For example,
HERV-K mRNA and proteins were detected in melanoma tis-
sues and cell lines (69, 70). A recent study identified 24 HERV-K
(HML-2) loci being transcribed in melanoma tissues (67). The
RT and its enzyme activity increase in breast cancer tissues and
hormone-treated cell lines (71). A large population (>85%) of
breast cancer patients express HERV-K Env proteins which elicit
both serologic and cell-mediated immune responses (72). HERV-
K virus-like particle production was observed in teratocarcinoma
cell lines (73, 74). HERV-K Gag and Env proteins are expressed
in germ cell tumors, and the patients produce antibodies against
these viral proteins (75, 76). Forward and reverse transcripts of
several HERV-K loci are detected in prostate cancer cell lines (77).
Furthermore, the gag gene of a HERV-H locus on chromosome
Xp22 is frequently expressed in colon cancer tissues (78). Ovarian
cancer tissues produce the Env proteins of HERV-K, ERV3, and
HERV-E (79).
TRANSCRIPTIONAL ACTIVATION OF HERVs BY EPIGENETIC
CHANGES IN CANCERS
Transposons undergo long-term epigenetic silencing by DNA
methylation, which is stably maintained from gametes to early
embryos and the adult tissues (80). Cancer-associated hypomethy-
lation, or derepression, frequently occurs in repeated DNA
sequences including heterochromatic DNA repeats, dispersed
retrotransposons, and endogenous retroviral elements (81).
Although genome wide hypomethylation in cancers seems to
be a side effect of carcinogenesis rather than the cause (82),
site-specific hypomethylation may possibly cause re-activation
of tumor-related genes leading to initiation and progression of
malignancies and other diseases (83).
Recent results show that increased HERV-K (22q11.23) expres-
sion in prostate and ovarian cancers is associated with hypomethy-
lation of the HERV-K locus (84, 85). Reduced methylation
of CpG dinucleotides within the promoter region corresponds
to HERV-W expression in ovarian cancer (86) and HERV-H
(Xp22.3) expression in colon, gastric, and pancreatic cancers
(87). Hypomethylation of the U3 region of several HERV-W
loci seems to be critical for the HERV-W activation in testicular
cancer (88).
IDENTIFICATION OF LTRs THAT CONTRIBUTE TO TUMOR
IMMUNITY AND ONCOGENESIS
A pioneering study identified a HERV-encoded peptide as a tumor-
specific antigen that works in the successful hematopoietic stem
cell transplantation for the therapy of metastatic renal cell carci-
noma (RCC) (89). The tumor antigen, CT-RCC-1, recognized by
RCC-specific CD8+ T cells is encoded by novel spliced variants
of the HERV-E transcript from chromosome 6q. Furthermore,
this antigen expression results from hypomethylation of the LTR
sequences, as well as hypoxia-inducible transcription factor (HIF-
2α) binding to the HIF responsive element (HRE) in the LTR (90).
HIF-2α is stabilized in many cases of RCC due to the von Hippel–
Lindau (VHL) tumor suppressor gene inactivation. This whole
scenario enlightens the relevance of HERVs in cancer biology and
treatment.
A study on tumorigenesis of Hodgkin’s lymphoma provided
the first and so far only evidence that endogenous LTR acti-
vation can be oncogenic (91). These malignant cells strongly
express CSF1R, the colony stimulating factor 1 receptor gene, to
allow CSF1/CSF1R-dependent cell growth. Intriguingly, a LTR of
THE1B (a MaLR family LTR retrotransposon) is located 6.2 kb
upstream of the CSF1R coding sequences, and is activated by the
loss of CpG methylation to drive the aberrant CSF1R gene expres-
sion from the initiation site within the LTR. The regulatory region
contains Sp1, GATA, AP-1, and NF-κB binding motifs. Anaplastic
large cell lymphomas also have the same CSF1R transcript. Thus,
hypomethylation of the THE1B LTR causes the CSF1R oncogene
activation, reminiscent of “insertional mutagenesis” by exogenous
retroviruses.
POSSIBLE CONTRIBUTION OF HERVs TO AUTOIMMUNE
DISEASES
Human endogenous retroviruses have also been implicated in
autoimmune diseases including rheumatoid arthritis (RA), mul-
tiple sclerosis (MS), and systemic lupus erythematosus (SLE).
Expression of multiple ERVs was detected in RA patients (92),
and that of HERV-K10 in juvenile RA (93). A recent report
indicated a strong linkage between the MS-associated retroviral
element (MRSV)-type HERV-W and MS: the env RNA and pro-
tein expression significantly increases in the blood and brain cells
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of MS patients (94). HERV-H/F family HERV-Fc1 expression in
T lymphocytes and the plasma HERV-Fc1 RNA level also increase
in patients with MS (95). HERV-K18 (chromosome 1) was found
to be a risk factor of MS (96) and other autoimmune disorders
(97, 98). Expression of HERV-W, K, E, and a newly identified
ERV-9/HERV-W variant in psoriasis was also observed (99).
Three mechanisms have been proposed for HERV-related
pathology of autoimmune diseases: molecular mimicry, superanti-
gen production, and LTR-mediated alterations of gene expression
(100). The Gag and Env proteins of HERV-K10 share the pep-
tide sequences with the rheumatoid factor epitopes on IgG1Fc,
implying molecular mimicry (101). The env genes of defective
HERV-K alleles at 1q21.2–q22 encode superantigens, and are
transcriptionally activated by the interferon α signaling to cause
polyclonal T-cell activation (102, 103). There was an interesting
hypothesis that solitary LTRs in the 5′-flanking region of the HLA-
DQB1 gene (encoding major histocompatibility complex, class
II, DQ beta 1) influence the susceptibility to autoimmune dis-
eases (104–106). However, these results remain ambiguous, and
need to be more critically examined to determine whether or
not the LTR/HERV activation is the true cause of the clinical
consequences (101, 107).
Furthermore, the LTR of MaLR family THE1D is activated
by transcription factor DUX4 which is specifically expressed in
facioscapulohumeral dystrophy, implying involvement of DUX4
in the pathophysiology (108). Hypomethylation of HERV-E and
HERV-K was also observed in SLE patients (109).
CONCLUDING REMARKS
Human endogenous retroviruses are remnant forms of infec-
tious retroviruses that integrated into the chromosomal DNA of
germ-line cells of human ancestors, increased their copy num-
bers and have been inherited by present-day humans. None of
the HERVs poses an immediate risk as a transposable element.
However, solitary LTRs derived from HERVs and MaLRs dom-
inate the provirus forms in the copy numbers, and can serve
as redundant enhancer-promoter sequences for nearby cellular
genes. When the DNA methylation-mediated suppression system
becomes compromised, HERVs and LTRs can cause detrimen-
tal and/or self-protecting effects. Two prominent examples of the
clinically significant HERV/LTR activation have been reported:
CSF1R oncogene activation by a MaLR LTR in Hodgkin’s lym-
phoma and RCC-specific novel HERV-E antigen expression facil-
itating the immunotherapy. Future researches in oncology and
immunogenetics will unveil more details about the endogenous
LTR functions in human pathogenesis.
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